On July 21, 2025, SAB Bio announced they’ve secured funding to run Phase 2 of their clinical trial in the United States in late 2025. Phase 1 of this clinical trial has been operating in Australia.
SAB Bio’s therapy aims to protect the cells in your pancreas from the T1D autoimmune attack. It starts with an innovative type of immunomodulator. This is not the same as an immunosuppressant. Instead, it changes how your immune system behaves without altering your daily immune protection — and with minimal side effects.
SAB Bio’s therapy is a type of immunoglobulin derived from human genes instead of an older type of immunoglobulin made from rabbits.
For decades, this rabbit-sourced immunomodulator therapy has been used for certain types of transplants — and it’s very effective. Unfortunately, it leads to “serum sickness” even with one dose and could never be dosed more than once.
SAB Bio’s human form of this thymoglobulin therapy means it does not cause serum sickness, and it can be dosed again without safety concerns.
Learn more about it in my past videos:
1. https://lnkd.in/etJ4W9zU
2. https://lnkd.in/e3KtaTgJ
Ginger Vieira has lived with type 1 diabetes since 1999 along with a few other chronic illnesses! She is the Cofounder of the Diabetes Nerd Network and the Diabetes Nerd Marketing agency. Ginger has authored hundreds of articles and several books, including Exercise with Type 1 Diabetes, Pregnancy with Type 1 Diabetes, Dealing with Diabetes Burnout, and Stop Overeating During Lows. Over her 20-year career (so far) in diabetes, she’s produced hundreds of articles and videos about life with diabetes. Her background includes a Bachelor of Science in professional writing and certifications in coaching, personal training, powerlifting, and Ashtanga yoga.